MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Earnings for MediWound Ltd. (MDWD)
Earnings in 2023 (TTM): $-6,531,000
According to MediWound Ltd.'s latest financial reports the company's current earnings (TTM) are $-6,531,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MediWound Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-6,531,000 | $-6,716,000 |
| 2022 | $-19,521,000 | $-19,599,000 |
| 2021 | $-13,524,000 | $-13,551,000 |
| 2020 | $-9,276,000 | $-9,601,000 |
| 2019 | $2.07 M | $3.72 M |
| 2018 | $-5,665,000 | $-1,057,000 |
| 2017 | $-14,533,000 | $-22,149,000 |
| 2016 | $-18,885,000 | $-18,885,000 |
| 2015 | $-21,671,000 | $-22,088,000 |
| 2014 | $-18,875,000 | $-18,875,000 |
| 2013 | $-8,501,000 | $-15,351,000 |
| 2012 | $11.99 M | $10.94 M |
| 2011 | $-4,819,000 | $-6,169,000 |